PAR · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 59/100 — Quality 55 · Valuation 86 · Momentum 25
| Share price | ₹102.57 |
| Market cap | ₹110 Cr |
| P/E ratio | 8.4 |
| P/B ratio | 1.0 |
| ROE | 106.6% |
| ROCE | 15.1% |
| Book value | ₹90.52 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹104 Cr | ₹13 Cr | 13.0% |
| 2025 | ₹101 Cr | ₹13 Cr | 15.7% |
| 2024 | ₹95 Cr | ₹14 Cr | 21.2% |
| 2023 | ₹95 Cr | ₹11 Cr | 15.3% |
| 2022 | — | — | — |
Par Drugs and Chemicals Limited develops, manufactures, and sells active pharmaceutical ingredients (APIs) and fine chemicals in India. The company provides API products, including magnesium hydroxide, magnesium oxide USP, sucralfate, almagate BP, dried aluminium hydroxide gel, light magnesium carbonate, magaldrate, magnesium trisilicate, colloidal silicon dioxide, aluminium magnesium silicate, magnesium aluminometasilicate, magnesium aluminosilicate-USP, magnesium oxide light, magnesium oxide heavy, magnesium aluminium hydrate, hydrotalcite, and synthetic aluminium silicate. It offers fine ch